Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Feb 1;191(3):241-3.
doi: 10.1164/rccm.201412-2264ED.

Bioactive lipids in emphysema. Decoding fat to reveal COPD phenotypes

Mehdi Mirzaie  1 , Farrah Kheradmand
Affiliations
Editorial

Bioactive lipids in emphysema. Decoding fat to reveal COPD phenotypes

Mehdi Mirzaie et al. Am J Respir Crit Care Med. .

Erratum in

No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The sphingolipid metabolic pathway associated with emphysema (left) and COPD exacerbation (right). Circles and rectangles represent the metabolites and enzymes, respectively. Red and green colors indicate positive and negative associations, respectively. Concentration of Cer, SM, and gangliosides are strongly and inversely associated with emphysema phenotype and glycolipids (trihexosylceramides, dihexosylceramides, ganglioside). Sulfatides are positively and S1P and SM are negatively associated with severe COPD exacerbation phenotype. 3-Keto = 3-ketosphinganine; Cer = ceramide; Cer-1P = ceramide-1 phosphate; COPD = chronic obstructive pulmonary disease; DHCer = dihyroceramide; EP = ethanolamine phosphate; GSL = glycosphingolipid; SM = sphingomyeline; SMase = sphingomyelinase; SMS = sphingomyelin synthase; SP = sphingosine; S1P = sphingosine-1-phosphate; Sph = sphinganine.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Vestbo J. COPD: definition and phenotypes. Clin Chest Med. 2014;35:1–6. - PubMed
    1. Vogelmeier C, Vestbo J. COPD assessment: I, II, III, IV and/or A, B, C, D. Eur Respir J. 2014;43:949–950. - PubMed
    1. Telenga ED, Hoffmann RF, Ruben t’Kindt, Hoonhorst SJM, Willemse BWM, van Oosterhout AJM, Heijink IH, van den Berge M, Jorge L, Sandra P, et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. Am J Respir Crit Care Med. 2014;190:155–164. - PubMed
    1. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, Spiegel S, Hla T. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 1998;279:1552–1555. - PubMed
    1. Thangada S, Khanna KM, Blaho VA, Oo ML, Im D-S, Guo C, Lefrancois L, Hla T. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med. 2010;207:1475–1483. - PMC - PubMed

MeSH terms

Substances